𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Philadelphia chromosome-positive thrombocythemia without features of chronic myeloid leukemia (CML) in peripheral blood

✍ Scribed by François Girodon; François Bailly; Marly Barry; Bernardine Favre; Paule-Marie Carli; Francine Mugneret; Jean Raymond Teyssier; Marc Maynadié

Publisher
Springer
Year
2005
Tongue
English
Weight
38 KB
Volume
84
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Fluorescence in situ hybridization (FISH
Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: A new strategy for remission assessment
✍ Josef Mühlmann; Josef Thaler; Wolfgang Hilbe; Oliver Bechter; Martin Erdel; Gerd 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 417 KB 👁 1 views

Interferon-␣ (IFN-␣) alone or in combination with cytostatic drugs can induce major and durable cytogenetic responses in about 20 to 25% of chronic myeloid leukemia (CML) patients. Since these patients have a significant survival benefit, more frequent follow-up investigations have become clinically

Thiotepa for the treatment of thrombocyt
Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia
✍ Edgardo J. Rodriguez-Monge; Jorge E. Cortes; Susan O'Brien; Moshe Talpaz; Hagop 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 3 views

## Background: Patients with chronic myelogenous leukemia (cml) occasionally experience persistent thrombocythemia despite having adequate white blood cell (wbc) counts. trimethylenethiophosphoramide (thiotepa) is an alkylating agent that significantly inhibits platelet production. ## Methods: Th

Location of breakpoints within the major
Location of breakpoints within the major breakpoint cluster region (bcr) in 33 patients with bcr rearrangement-positive chronic myeloid leukemia (CML) with complex or absent Philadelphia chromosomes
✍ Dr. Ian Dubé; Julie Dixon; Teresa Beckett; Abraham Grossman; Martha Weinstein; P 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 460 KB

We report the sublocalization of the breakpoint in chromosome 22 in 33 patients with chronic myeloid leukemia (CML) who also had unusual marrow cytogenetics. In 23 patients, the leukemic clones were characterized by Philadelphia (Ph') chromosomes that arose through complex translocations that involv

Expanding Nilotinib Access in Clinical T
Expanding Nilotinib Access in Clinical Trials (ENACT) : An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase
✍ Franck E. Nicolini; Anna Turkina; Zhi-Xiang Shen; Neil Gallagher; Saengsuree Joo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB 👁 2 views

## Abstract ## BACKGROUND: Nilotinib is a selective, potent BCR‐ABL inhibitor. Previous studies demonstrated the efficacy and safety of nilotinib in Philadelphia chromosome‐positive chronic myeloid leukemia patients in chronic phase (CML‐CP) or accelerated phase who failed prior imatinib. ## METH